Post My Press Release

Free Press Release Distribution

Category: Hospitals (Page 1 of 24)

Virginiamycin Market Moving Toward 2026 With New Procedures

Virginiamycin is an antibiotic produced by Streptomyces virginiae and belongs to the streptogramin group, which has two synergistic factors: M (hybrid polyketide-peptide) and S (peptide). It is used in the fuel ethanol industry to prevent microbial contamination. Virginiamycin is an antibiotic, which was marketed for vancomycin resistant enterococcus in the U.S. in 1999. It is also used in the agriculture sector specifically in livestock to accelerate the growth of animals and prevent and treat infections. Virginiamycin is a mixture of two principle components of virginiamycin M1 and virginiamycin S1. Virginiamycin controls microbial growth within lumen of gastrointestinal tract by disrupting bacterial protein synthesis. Click To Read More On Virginiamycin Market.

Virginiamycin can also be used as a growth stimulator as it optimizes the absorption and metabolism of nutrients. It also improves the state of small intestine epithelium and inhibits the growth of harmful toxins and metabolites by gut organisms. Virginiamycin is used for the treatment of necrotic enteritis in broiler chickens — a common fatal gastrointestinal disease in poultry.

Virginiamycin Market- Dynamics

Pharmaceutical manufacturers are focused launching new products to address limited availability of Virginiamycin and to enhance their market share. This in turn is expected to augment the market growth. For instance, in January 2019, Phibro Animal Health Corp. announced that its virginiamycin medicated feed additive received regulatory approval by Veterinary Drugs Directorate (VDD), Health Canada, for use in beef cattle. According to Phibro Animal Health Corp., V-max (virginiamycin) is approved for the reduction of incidence of liver abscesses in cattle fed in confinement.

In developing countries there is rapid increase of demand for livestock. In developed countries, demand for livestock is stagnating. Increasing demand for livestock due to growing human population is expected to boost growth of the market. Increasing livestock production leads to high demand for animal feed.

Stringent regulations by the regulatory agencies is expected to hinder market growth. In September 2015, the European Commission adopted the regulation establishing maximum residue limits for virginiamycin in poultry species, which is valid throughout the European Union.

Virginiamycin Market- Competitive Analysis

Key players in the market are focused on development, manufacturing, and marketing of multisource and branded pharmaceuticals, thereby augmenting the market growth. For instance, in January 2017, Huvepharma AD received approval for STAFAC (virginiamycin) plus CLINACOX (diclazuril) combination drug type in chickens for prevention of necrotic enteritis and coccidiosis in broiler chickens.

Ask For Sample Copy Of This Business Research Report : https://www.coherentmarketinsights.com/insight/request-sample/2621

Key players operating in the global virginiamycin market include, Hongcong Xinrunde Chemical Co., Ltd, Xiamen ShengLang SaiChuang Biological Technology Co., Ltd., Manus Aktteva Biopharma, Alfanzyme, Phibro Animal Health Corporation, Merck Animal Health, Zoetis, Elanco, Virbac, Ceva, and Vetoquinol.

Virginiamycin Market- Regional Dynamics

On the basis of region, the global virginiamycin market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. The rapid increase in livestock animals is the main reason for North America region to hold a dominant position in the global virginiamycin market over the forecast period in terms of revenue share followed by Europe. The virginiamycin market in this region has been growing due to the necessity for the additional supplements in the diet for a companion as well as livestock animals for appropriate nutrition. The consumption of virginiamycin is high in Europe, which is expected to drive the virginiamycin market growth in the region. For instance, in January 2017, virginiamycin was approved for use in feed. Upon completion of voluntary conversion from over the counter to veterinary feed directive(VFD), all feed uses of the virginiamycin alone or in a combination, will require the VFD. The proprietary drug names of virginiamycin is Stafac and V-max.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

Hospital Pharmaceuticals Market: Competitive Dynamics & Global Outlook 2026

Hospital pharmaceutical consists of pharmaceuticals which are purchased by hospitals and used for treatment of either inpatients or outpatients. Hospital pharmaceutical drugs includes critical care and therapeutic drugs applied in infections, alimentary tract and metabolism, cardiology, urology, neurology, sensory organs, musculoskeletal system, respiratory system, dermatology, hematology and other. The primary responsibility of hospital pharmacy is procurement, storage and selling of medications. Hospital pharmaceuticals consists of medicines purchased for hospitals, healthcare centers in order to be administered to patients during hospital enabled treatment period.
The procurement of hospital pharmaceuticals for inpatients are not regulated by any legislation. Price of hospital pharmaceuticals are based on the negotiations between the hospital pharmacy and pharmaceutical company, especially in case of bulk purchases. However, hospital pharmacies are free to negotiate purchasing price with the industries officials depending on hospital needs and competition between the suppliers in market to receive hospital formulary.
Request Sample Copy of This Research: https://www.coherentmarketinsights.com/insight/request-sample/2611
For instance, Pharmac, a New Zealand government agency takes the decision about which medicines should be publically funded to help the patients get medicines at subsidized price and make choices on spending of District Health Board (DHB) on medical treatments. Pharmac with their increased horizon in vaccines, haemophilia treatments, cancer treatments and hospital medicines segment takes decisions on medicines funded in DHB hospitals and negotiates on budget management of hospital medicines. Pharmac publishes the list of subsidiarised medicine and drugs in their pharmaceutical schedule, annually. Pharmaceutical schedule list consists of formulations, doses, subsidy price of medicine and prescribing guidelines and it made accessible to health professionals and pharmacists.
Hospital Pharmaceuticals Market Drivers:High prevalence of chronic diseases is a major factor driving the hospital pharmaceuticals market. According to the World Health Organization (WHO), in 2015 around 17.7 million people died due the cause of cardiovascular disease (CVD), representing 31% of all world deaths. Over three quarters of the total CVD deaths take place in low and middle income countries, indicating in the need for better medications in such regions. According to WHO, globally 8.8 million people died due to the cause of cancer in 2015, which majorly includes lung, stomach, liver, colorectal and female breast cancer. According to data published by National Center for Complementary and Integrative Health (NCCIH), in August 2015, 25.3 million U.S. people were suffered from daily pain.
Hospital Pharmaceuticals Market Taxonomy:By Therapeutic application:

  • Cardiology
  • Oncology
  • Nephrology
  • Urology
  • Neurology
  • Pain & Infection

According to the report published by, NORC at the University of Chicago, in October 2016, 90% of hospital administrators in U.S. reported that, the increased drug prices during the period 2013 to 2015, and growth in inpatient drug spending made the moderate to severe impact on hospital pharmaceutical budget. The major findings by Federation of American Hospitals (FAH) highlighted that inpatient spending increased by 38.7% on per hospital admission, from 2013 to 2015, affecting hospitals ability to manage overall healthcare costs. The large and uncertain increase in the hospital associated drug cost could significantly impact the hospitals’ ability to manage cost within the Medicare’s fixed price based payment system.
Hospital Pharmaceuticals Market Competitive Analysis:Key players operating in the hospital pharmaceuticals market includes Bayer AG, Novartis AG, Pfizer, Inc., AstraZeneca plc, GlaxoSmithKline plc, Johnson & Johnson, F. Hoffmann-La Roche Ltd, Sanofi S.A., Merck & Co., Inc. and Eli Lilly and Company.
Click To Read More On Hospital Pharmaceuticals Market
About Coherent Market Insights:Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Bipolar Disorders Treatment Market Revenue Growth Predicted by 2026

Bipolar disorder is related to mental health and can be characterized as drastic changes in mood, energy levels, and ability to perform daily tasks. The mood typically shows two types of episodes – manic and depression. There are four types of bipolar disorders: Bipolar I, Bipolar II, Cyclothymic, and other specified and non-specified bipolar and related disorders. All these types show similar symptoms but the severity varies. Bipolar disorder can be treated with treatments such as mood stabilizers, antipsychotics, antidepressants, and anticonvulsants. Click To Read More On Bipolar Disorders Treatment Market.

Global Bipolar Disorders Treatment Market Drivers

Key players in the global bipolar disorder treatment market are focusing on research and development of novel drugs that aid in the treatment of bipolar disorders. This in turn is expected to drive the global bipolar disorder market growth. For instance, in February 2019, Otsuka Holdings Co. Ltd. reported Phase III clinical trial evaluation of brexpiprazole for the treatment of manic attacks in bipolar disorder I. The study was conducted to confirm the effectiveness of brexpiprazole for a duration of 2-3 weeks, in double-blind and placebo-controlled trials. It was found that the drug was well tolerated by the patients.

Furthermore, in July 2018, a team of researchers from Novartis International AG studied on digital measurement tools for bipolar disorders so that accurate drug can be given for an effective treatment. Until now, these disorders are identified by conventional methods and no definitive tool is available, which tests the spinal fluid present in the brain. According to the researchers, these digital measurement tools may help in diagnosis of bipolar disorder and will increase the efficacy of drugs.

Moreover, intervention of medical adherence tools (such as electronic adherence monitoring devices) to increase treatment adherence in patients with bipolar disorders may improve outcomes in the treatment of bipolar disorder patients. It ensures that medication is properly taken and it is done so by ways such as psychoeducational and family communication interventions, cognitive behavior therapy, manipulating the packaging of the drugs, simplifying a dosage regimen with pill boxes, medication organizers, blister packaging, or coordinating dosage times with the daily activities of patients.

Global Bipolar Disorders Treatment Market Key Players

Some of the major players operating in the global bipolar disorder treatment market include, Pfizer Inc., Eli Lilly and Co, Apotex Technology Inc., AbbVie Inc., Novartis AG, Otsuka holdings co. Ltd., GlaxoSmithKline LLC, AstraZeneca, Allergan plc., and Janssen Pharmaceuticals Inc.

Ask For Sample Copy Of This Business Research Report : https://www.coherentmarketinsights.com/insight/request-sample/2605

Global Bipolar Disorders Treatment Market Regional Analysis

North America is expected to hold dominant position in the global bipolar disorder treatment market. Presence of leading manufacturers such as Eli Lilly and Co., Pfizer Inc., and AbbVie Inc in the region has supported North America bipolar disorders treatment market. Moreover, ongoing research and development in bipolar disorder treatments by companies such as Sage Therapeutics is expected to support North America bipolar disorders treatment market growth over the forecast period. For instance, Sage Therapeutics is working on Sage-217 drug for major depressive episode of bipolar disorder. The drug has completed phase-II of clinical trials in March 2019. Such key developments are expected to boost the global bipolar disorder treatment market growth.

Furthermore, key players from other markets have also received approvals for their novel products in the U.S. For instance, Allergan (Ireland-based company) received Supplemental New Drug Application (sNDA) expansion on Varylar in 2017, which aids in the treatment of bipolar disorders.

Moreover, increasing initiatives from various governments and organizations to spread awareness regarding mental health also supports the global bipolar disorders treatment market growth. For instance, Mental Health America celebrates the month of May as the Mental Awareness Month. The organization offers various other organizations a toolkit designed for the patients with chronic conditions. These factors are expected to support global bipolar disorders treatment market growth over the forecast period.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

Global Dental Equipment Market Evolving Industry Trends To 2026

The global dental equipment market was valued at US$ 6,342.3 million in 2015 and is expected to expand at a CAGR of 4.7% during the forecast period (2016 – 2024). Practice of dentists has shifted from being focused on disease treatment to preventive measures. This change in market dynamics is acting as a catalyst for development of new technologies for diagnosis and treatment of dental issues Growing awareness about dental care among consumers has translated into rising number of routine-check-ups and growing spending on maintaining oral health. This is in turn spurring demand for dental care equipment, including dental lasers, imaging systems, and computer-aided design and computer-aided manufacturing (CAD/CAM) systems. Click To Read More On Global Dental Equipment Market.

Market Dynamics

Dental equipment finds extensive application in diagnosis and treatment of dental disorders such as dental cavities, gingival disease, and periodontal (gum) disease. Advent of 3D printing in dental industry creates a highly favorable environment conducive for market growth and helps dentists provide better services through use of highly efficient diagnostic and treatment tools. Moreover, growing public awareness about dental treatment options, coupled with increasing expenditure on dental care is driving patients to opt for preventive measures. According to a study published in the American Dental Association’s research paper of 2014, around 52.3% of adults in the U.S. visited a dentist every six months. Focus on enhancing patient’s experience through high-quality treatment outcomes is driving demand for dental equipment worldwide.

Development of CAD/CAM & 3D printing is expected to drive dental equipment market growth

Incision during surgeries can be carried out precisely by using laser and electro surgery techniques. This will reduce the damage caused to tissues and will aid in faster healing. The time taken for prosthodontic restoration procedures has reduced to one day due to the development of CAD/CAM. By replacing conventional radiology equipment with digital radiology equipment equipped with picture archiving and communication systems (PACS), treatment records can be archived. Moreover, outcomes of dental treatments have improved due to 3D printing technology. When compared to the conventional CT systems, cone beam CT systems provides clear extra oral images and exposure to harmful X-rays will be minimal.

Key companies covered as a part of this study include A-Dec Inc., 3M ESPE, Carestream Heath, Inc., Biolase Inc., Noble Biocare, Danaher Corporation, Ivoclar Vivadent AG, Dentsply Sirona, Inc., Henry Schein, Inc., Patterson Companies Inc., Planmeca Oy, and Institut Straumann AG.

Ask For Sample Copy Of This Business Research Report : https://www.coherentmarketinsights.com/insight/request-sample/85

High treatment costs in developed economies fueling influx of dental tourists in emerging economies

According to the New National Survey published in the American Dental Association in 2014, 40.2% of adults in the U.S. indicated that they would forego dental care due to high costs associated with it. According to 2016 statistics of the Oral Health Foundation, 88% of adults in the U.K. do not have dental insurance and around 63% of adults prefer visiting National Health Service (NHS) dentists rather than private dentists due to high costs associated with the later. High dental cost involved in cosmetic dentistry dental caries, periodontal disease treatment and overall dental care in developed economies is fueling growth of dental tourism in emerging regions such as Asia, Latin America, and Eastern Europe. Rapid development of dental tourism hubs such as India and Brazil would spur growth of the dental equipment market in emerging regions.

Increasing preference for refurbished dental equipment impacting the growth of overall dental equipment market

Budget constraints in emerging countries such as India, China, Brazil and Eastern European countries is driving demand for refurbished dental equipment. This aids the newly established dental clinics and laboratories to achieve cost-efficiency with quality throughput. New dental equipment such as cone beam CT systems, vacuums & compressors, cad/cam, digital X-ray units and laboratory equipment involve high capital investment. This may increase the cost of patient dental procedures, thus negatively impacting the number of patient visits.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

Fibrosarcoma Drugs Market Trends Estimates High Demand by 2026

Fibrosarcoma is a rare type of soft tissue malignant tumour composed solely of fibre-forming connective tissue called as fibroblasts. Although, this condition can occur at any age, it is commonly diagnosed between the age of 30-60 years. Patients suffering from genetic conditions such as retinoblastoma, nevoid basal cell carcinoma syndrome are more prone to develop fibrosarcoma. However, precise cause of disease is unknown. Furthermore, individuals undergoing radiation therapy or having lymphedema or get exposed to chemicals such as thorium dioxide vinyl chloride or arsenic are more prone to fibrosarcoma. This disease is symptomized by muscular pain, which increases exponentially with time. Click To Read More On Fibrosarcoma Drugs Market.

It is diagnosed by bone lesions in radiograph, followed by advanced imaging and laboratory test and confirmed by biopsy results. Treatment of the disease depends on the stage of tumour during diagnosis. Surgery and radiation therapy are the treatment used for fibrosarcoma. Currently, limited number of treatment methods and various side effects of chemotherapy such as hair loss or low blood platelet count are propelling demand for research and development activities in fibrosarcoma treatment.

Fibrosarcoma Drugs Market Driver

Increasing research activities are expected to fuel the growth of fibrosarcoma drugs market over the forecast period. Fibrosarcoma being malignant tumor requires early removal through complete eradication of malignant cells by chemotherapy. Currently available chemotherapy includes side-effects such as acquirance of multi-drug resistance (MDR), severe side-effects and high rate of reoccurrence, which in turn demands for safer drug for chemotherapy. For instance, Loxo Oncology Inc., 2017, received US FDA approval for investigational new drug application for LOXO 195, a next-generation TRK inhibitor for treatment of patients with cancers that have acquired resistance to initial TRK therapy such as larotrectinib. Moreover, in the same year, LOXO oncology announced partnership with Bayer for the global development and commercialization of Larotrectinib and LOXO-195. The novel drug combination studies, clinical trial for targeted drug delivery and genetic profile based medication are expected to boost growth of the fibrosarcoma drugs market over the forecast period.

Fibrosarcoma Drugs Market- Competitor

Major players operating in fibrosarcoma drugs market include Cadila Healthcare Limited, Bristol-Myers Squibb Company, Dr. Reddy’s Laboratories Ltd., Sun Pharmaceutical Industries Ltd., Baxter International Inc., Eli Lilly and Company, Pfizer limited, Johnson & Johnson., and Celon Laboratories Pvt. Ltd.

Ask For Sample Copy Of This Business Research Report : https://www.coherentmarketinsights.com/insight/request-sample/1495

Increasing prevalence of fibrosarcoma is expected to augment growth of the fibrosarcoma drugs market. According to American Society of Clinical Oncology, 2017, around 3260 individuals were diagnosed by primary bone cancer in U.S. out of which 4% of adults are suffering from fibrosarcoma and prevalence of the disease is higher in men than in women. Currently, diagnosis facility lacks in early and accurate detection of fibrosarcoma. Therefore, rising awareness for disease and advancement in diagnostic as well as therapeutic procedures are expected to propel growth of the fibrosarcoma drugs market. Furthermore, companies, universities, and institutes are taking initiatives to provide inexpensive, readily available drugs with less side-effects as compared to present drugs that will help key players to strengthen product portfolio, in turn driving growth of the fibrosarcoma drug market. Key players as well as government organization such as Nation Cancer Institute or American Society of Clinical Oncology sponsors or collaborate for the development of novel therapies and drugs. For instance, Bayer partners with loxo oncology to develop and commercialise cancer therapies.

Fibrosarcoma Drugs Market- Regional Analysis

The global fibrosarcoma market is projected to hold dominant position in North America over the forecast period, due to increasing research activities leading to better fibrosarcoma treatment. Furthermore, well-developed healthcare infrastructure is fuelling growth of fibrosarcoma market. Asia Pacific is expected to be fastest growing market over the forecast period due to developing healthcare infrastructure and rising awareness regarding conditions of fibrosarcoma.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

Interventional Neurology Market To Grow Like Never Before By 2026

According to the Brain Aneurysm Foundation (BAF), brain aneurysm accounts for around 500,000 deaths each year. BAF estimates that aneurysm is predominant in the age group of 35–60 years. Moreover, globally around 15 million people suffer a stroke every year, as per stats released by the World Heart Federation. High incidence of stroke and brain aneurysm is contributing to increasing demand for interventional neurology devices. Furthermore, introduction of new techniques such as flow diverter and aspiration are propelling demand for interventional neurology devices. The global Interventional neurology market was valued at US$ 1,694.5 million in 2015 and is expected to expand at a CAGR of 5.3% during the forecast period (2016 – 2024). Click To Read More On Interventional Neurology Market.

Neurovascular conditions such as stroke and aneurysms are generally treated with tissue plasminogen activators (tPAs). However, use of neurointerventional devices along with the medication therapy is more effective in removing clots and reducing the risk of early recurrence of the condition. Interventional neurology technology has been evolving rapidly, which is resulting in demand shift from clipping to coiling, coated to bare platinum coils, and so on.

Market dynamics

Factors such as increasing prevalence of brain aneurysms, and stroke, government programs to decrease the burden of traumatic brain injury, technological advancements plugging treatment gaps and availability of reimbursement are driving demand for neurointerventional devices. However, high cost and negative perception about neurointerventional devices is impacting the demand negatively. Companies are therefore, adopting different strategies such as providing FDA approved on-site training, strategic collaborations, and technology upgrades in order to increase their market presence and engage with customers.

Innovative neurointerventional devices to cannibalize conventional neurointerventional devices

Coiling is the conventional and more of a gold standard treatment technique for stroke. Increasing complexities in treating patients suffering from recurring stroke incidents is driving demand for advanced technological products. Neurointerventional devices such as Intrasaccular devices, stent retrievers, and flow diverters are expected to gain major traction during the forecast period (2016 – 2024). Intrasaccular devices are expected to be launched in the U.S. and Japan market by 2018. Realizing the benefits of stent retrievers, the American Heart Association and American Stroke Association have issued guidelines, recommending the use of stent retrievers along with tPA for treatment of stroke.

Strategic channel distribution agreements among manufacturers to bolster their regional reach

Codman Neuro entered into agreement with InNeuroCo, Inc. for the European distribution rights for intermediate catheters (ICs). Similarly, Covidien (now Medtronic) entered into an exclusive distribution agreement with Pulsar Vascular, Inc. to market and promote PulseRider in Europe, the Middle East, and Africa. PulseRider is a minimally invasive device intended for use (with embolic coils) for treatment of unruptured wide-neck intracranial aneurysms. Such strategic distribution partnership are helping market leaders to expand their global footprint.

Ask For Sample Copy Of This Business Research Report : https://www.coherentmarketinsights.com/insight/request-sample/56

Penumbra 3D Revascularization Device (next-generation stroke-treatment device) proved more effective with Penumbra aspiration device according to the studies conducted by Penumbra, Inc. as compared to using the aspiration device alone.

Market players need to address demand-shift in devices and procedural techniques

The global Interventional neurology market is undergoing a demand-shift in terms of products and techniques to treat stroke and aneurysms. For instance, demand for bare platinum coils is growing at a rapid pace as compared to that for coated coils. This is mainly due to high costs of coated coils and their less improved clinical outcomes compared to bare platinum coils. The highly touted International Subarachnoid Aneurysm Trial (ISAT) demonstrated improved clinical outcomes with coils rather than clipping, which resulted in decline in the usage of clips in neurovascular surgery.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

Hospice & Palliative Care Centers Market Foreseen To Grow Exponentially Over 2026

Hospices & palliative care is a type of care that offers support and care for patients during their last phase of life. It focuses on critically ill patient’s pain and symptoms, and attending to their spiritual and emotional needs, with an approach to improve the life of patients and their families associated with life-threatening illness. Hospice care can be offered by autonomous hospices or through programs based in nursing homes, health care organization, outpatient clinics and hospitals. It can also be offered in the nursing home, patient’s home, a hospital, or private hospice facility. Home hospice care is usually less expensive than that provided in hospitals, nursing homes, or other institutional settings as the cost of additional staff and highly equipped facilities is circumvented when at home. Moreover, patients prefer hospice care as the patient desires to spend the rest of life with loved ones at home. Click To Read More On Hospice & Palliative Care Centers Market

Due to an aging U.S. population, and sustained federal reimbursement, the growth of hospice and palliative care sector is increasing rapidly. Companies are also following marketing strategies for converting their companies into profit making organizations.

The global hospice & palliative care centers market is segmented on the basis of service type. Type of hospices & palliative care services includes Institutional care , nursing care, physician services, trained volunteer support, social services, spiritual support and counseling, home health aides, physical, and occupational, speech therapies, inpatient care, respite care, bereavement support and adult day care services. Based on the location, the hospice and palliative care centers market is analyzed for patient’s residence, hospice inpatient facility and acute care hospital.

According to the National Hospice and Palliative Care organization (NHPCO), in 2014 approximately 1.6 to 1.7 million patients received services from hospice care centers. Nearly 60% of the hospice care in 2014 was provided at patient’s residence.

Aging population will be the major driving factor

The hospice & palliative care centers market is driven by various factors including:

  • Reimbursement from Medicaid and Medicare
  • Aging population
  • Increasing healthcare expenditure and a common drift toward end-of-life care

According to the Centers for Disease Control and Prevention (CDC), there were 40 million people (13% of the total population) aged 65 and above in the United States in 2010. This is projected to reach around 20% of the population of the U.S. by 2030. Furthermore, the NHPCO reports that in 2014, more than 60% of the hospice care was for the people aged 75 years and above in the U.S.

Ask For Sample Copy Of This Business Research Report : https://www.coherentmarketinsights.com/insight/request-sample/34

Major Players in the Global Hospice and Palliative Care Centers Market

Some of the key global participants present in the hospice & palliative care centers market include Vitas Healthcare Corporation, Skilled Healthcare Group Incorporated, Sunrise Senior Living, LLC , Kindred Healthcare Incorporated, Gentiva Health Services Incorporated, Home Instead Senior Care Incorporated, Amedisys Incorporated, Skilled Healthcare Group Incorporated, Genesis HealthCare Corporation, Senior Care Centers of America, and GGNSC Holdings LLC.

Demand still high in the Developed Markets

Geographically, the hospice & palliative care centers market is segmented into North America, Europe, Asia Pacific, Latin America and Rest of the World. Hospice and palliative care centers are now recognized as a medical subspecialty by the American Board of Medical Specialties, as well as in Australia, Canada, England, New Zealand, and Ireland. Many European countries are also in the process of developing certification for palliative care. Most private health insurance companies include hospice care as a benefit. Some hospices are able to provide services without charge if a patient has limited or no financial resources. Hospice care expenses in U.S. are mostly paid by the Medicare and Medicaid services and the Department of Veterans Affairs.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

Caps & Closures Market is expected to witness a CAGR of more than 5.62% between 2016 and 2021

[199 Pages report] The Caps & Closures Market size is estimated to grow from USD 49.78 Billion in 2015 to USD 68.71 Billion by 2021, at a CAGR of 5.62%. The base year considered for the study is 2015 and the market size is projected from 2016 to 2021. The report covers study of the various segments that are part of the manufacturing process of caps & closures and the end consumers. Thus, segmentation for the caps & closures market includes by raw material, type, and application. The report covers detail study on key parameters such as market drivers, restraints, opportunity and challenges which is hindering growth of this industry. The report also aims to study the individual growth trends, future prospects, and contribution of various segments to the total market.

Request for free sample report: https://www.marketsandmarkets.com/requestsampleNew.asp?id=1314

Table of Contents

1 Introduction

2 Research Methodology

3 Executive Summary

4 Premium Insights

5 Market Overview

6 Caps & Closures Market, By Raw Material

7 Caps & Closures Market, By Type

8 Caps & Closures Market, By End-Use Industry

9 Caps & Closures Market, By Region

10 Competitive Landscape

11 Company Profiles

12 Appendix

The beverages segment dominated the market in 2015 and is projected to be the second-fastest-growing end-user industry in the next five years, as a result of the rising consumer demand for beverage products such as bottled water and beer as well as growing demand for quality and safe products. Furthermore, the healthcare segment is projected to be the fastest-growing end-use industry due to the rising consumption of pharmaceutical and medical products.

The Asia-Pacific region leads the market due to its large population and its proven identity of a major manufacturing hub that offers production opportunities at affordable costs to companies. As caps & closures are used widely by different industries, such as food, beverages, and healthcare, the Asia-Pacific region, which is witnessing major growth in these sectors as well, has become a large market for these packaging solutions. This is followed by North America, which is the next largest market for caps & closures followed by Europe and Rest of the World.

The global market for caps and closures is dominated by players such as RPC Group Plc (U.K.), Reynolds Group Holdings Limited (New Zealand), Crown Holdings Inc. (U.S.), Amcor Limited (Australia), Rexam PLC (U.K.), Berry Plastics Corporation (U.S.), Silgan Holdings Inc. (U.S.), AptarGroup Inc. (U.S.), Guala Closures Group (Italy), and BERICAP GmbH Co. & KG (Germany).

Early buyers will receive 10% customization on this report.

Don’t miss out on business opportunities in Caps & Closures Market.

Read Our blog for more details: http://bit.ly/2DlIYqB

About MarketsandMarkets

MarketsandMarkets is the largest market research firm worldwide in terms of annually published premium market research reports. Serving 1700 global fortune enterprises with more than 1200 premium studies in a year, M&M is catering to a multitude of clients across 8 different industrial verticals. We specialize in consulting assignments and business research across high growth markets, cutting edge technologies and newer applications.

Contact:
Mr. Shelly Singh
MarketsandMarkets™ INC. 
630 Dundee Road 
Suite 430 
Northbrook, IL 60062 
USA: 1-888-600-6441 
sales@marketsandmarkets.com

Page 1 of 24

Powered by WordPress & Theme by Anders Norén